These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8839903)

  • 21. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
    ; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
    J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
    Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
    J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokinetic parameters of locally advanced human breast cancer treated with diethylstilbestrol and chemotherapy.
    Conte PF; Alama A; Di Marco E; Canavese G; Rosso R; Nicolin A
    Basic Appl Histochem; 1986; 30(2):227-31. PubMed ID: 3755591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
    Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
    Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
    Saeki T; Takashima S; Ogita M; Tabei T; Adachi I; Tamura K; Takatsuka Y; Kanda K
    Breast Cancer; 2006; 13(2):159-65. PubMed ID: 16755111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
    Radice D; Redaelli A
    Pharmacoeconomics; 2005; 23(1):69-75. PubMed ID: 15693729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
    Hui R; Zhang M; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
    Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
    Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
    Gabra H; Cameron DA; Lee LE; Mackay J; Leonard RC
    Br J Cancer; 1996 Dec; 74(12):2008-12. PubMed ID: 8980405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.